History & Locations

Glaukos milestone achievements

1998

Glaukos founded and incorporated.

2001

The first human implant of Glaukos micro-bypass glaucoma stent is performed. Glaukos Corporation commences operations.

2008

In consultation with, and with the approval of the American Academy of Ophthalmology (AAO), Glaukos applies for and received a Category III CPT code to describe insertion of a flow device into the trabecular meshwork.

2012

iStent is approved by FDA for insertion in combination with cataract surgery and becomes the first MIGS device commercially available in the United States. [Important Safety Information]

2014

Glaukos establishes direct sales organization and launches iStent inject® in Germany.

2016

iStent approved in Japan. Glaukos establishes direct sales organization and launches iStent inject in Australia and Canada. New Glaukos headquarters is established in San Clemente, California.

2018

Glaukos commences U.S. launch of iStent inject following FDA approval for use in combination with cataract surgery. [Important Safety Information] Glaukos commences Phase III IND clinical trials for iDose Travoprost. Glaukos commences an FDA clinical trial for iStent infinite. Glaukos enters pharmaceutical development agreement with D. Western Therapeutics Institute, Inc., preeminent research organization for proprietary Rho Kinase Inhibitor compounds.


1999

Glaukos produces first model of micro-bypass glaucoma stent.

2005

Glaukos commences U.S. IDE clinical trial to evaluate iStent® in conjunction with cataract surgery; this landmark trial is the first of its kind ever conducted in support of a glaucoma device.

2011

In consultation with, and with the approval of the AAO, Glaukos applies for and received a Category III CPT code to describe insertion of a flow device into the suprachoroidal space.

2013

100% Medicare coverage for iStent procedure is secured.

2015

Glaukos completes patient enrollment of U.S. IDE pivotal trial to evaluate iStent inject in combination with cataract surgery. Glaukos completes initial public offering and common stock begins trading on New York Stock Exchange under ticker GKOS.

2017

Glaukos global direct sales operations expands to 17 countries and more than 170 professionals. iStent inject is approved in Brazil, Israel, Malaysia, Saudi Arabia, and Singapore. Glaukos completes Phase II IND clinical trial for iDose Travoprost. Glaukos acquires early-stage intraocular pressure sensor system assets to complement its micro-scale surgical and drug delivery technology platforms.

2019

Total number of iStent devices implanted exceeds 500,000. Glaukos enters the corneal health market with the acquisition of Avedro, maker of the first and only FDA-approved cross-linking technology for progressive keratoconus. Glaukos concludes patient enrollment of the clinical trial for iStent infinite. Glaukos announces the collaboration and distribution agreement with Santen for exclusive distribution of the MicroShunt (DE-128) for patients with refractory glaucoma in the United States. Glaukos announces agreement with Intratus, Inc., to research, develop, manufacture and commercialize Intratus’ patented, non-invasive drug delivery platform designed for use in the treatment of dry eye disease, glaucoma and other corneal disorders, such as allergy, blepharitis, conjunctivitis and related conditions.

1998

Glaukos founded and incorporated.

1999

Glaukos produces first model of micro-bypass glaucoma stent.

2001

The first human implant of Glaukos micro-bypass glaucoma stent is performed. Glaukos Corporation commences operations.

2005

Glaukos commences U.S. IDE clinical trial to evaluate iStent® in conjunction with cataract surgery; this landmark trial is the first of its kind ever conducted in support of a glaucoma device.

2008

In consultation with, and with the approval of the American Academy of Ophthalmology (AAO), Glaukos applies for and received a Category III CPT code to describe insertion of a flow device into the trabecular meshwork.

2011

In consultation with, and with the approval of the AAO, Glaukos applies for and received a Category III CPT code to describe insertion of a flow device into the suprachoroidal space.

2012

iStent is approved by FDA for insertion in combination with cataract surgery and becomes the first MIGS device commercially available in the United States. [Important Safety Information]

2013

100% Medicare coverage for iStent procedure is secured.

2014

Glaukos establishes direct sales organization and launches iStent inject® in Germany.

2015

Glaukos completes patient enrollment of U.S. IDE pivotal trial to evaluate iStent inject in combination with cataract surgery. Glaukos completes initial public offering and common stock begins trading on New York Stock Exchange under ticker GKOS.

2016

iStent approved in Japan. Glaukos establishes direct sales organization and launches iStent inject in Australia and Canada. New Glaukos headquarters is established in San Clemente, California.

2017

Glaukos global direct sales operations expands to 17 countries and more than 170 professionals. iStent inject is approved in Brazil, Israel, Malaysia, Saudi Arabia, and Singapore. Glaukos completes Phase II IND clinical trial for iDose Travoprost. Glaukos acquires early-stage intraocular pressure sensor system assets to complement its micro-scale surgical and drug delivery technology platforms.

2018

Glaukos commences U.S. launch of iStent inject following FDA approval for use in combination with cataract surgery. [Important Safety Information] Glaukos commences Phase III IND clinical trials for iDose Travoprost. Glaukos commences an FDA clinical trial for iStent infinite. Glaukos enters pharmaceutical development agreement with D. Western Therapeutics Institute, Inc., preeminent research organization for proprietary Rho Kinase Inhibitor compounds.

2019

Total number of iStent devices implanted exceeds 500,000. Glaukos enters the corneal health market with the acquisition of Avedro, maker of the first and only FDA-approved cross-linking technology for progressive keratoconus. Glaukos concludes patient enrollment of the clinical trial for iStent infinite. Glaukos announces the collaboration and distribution agreement with Santen for exclusive distribution of the MicroShunt (DE-128) for patients with refractory glaucoma in the United States. Glaukos announces agreement with Intratus, Inc., to research, develop, manufacture and commercialize Intratus’ patented, non-invasive drug delivery platform designed for use in the treatment of dry eye disease, glaucoma and other corneal disorders, such as allergy, blepharitis, conjunctivitis and related conditions.


Empowering ophthalmic
growth worldwide

With direct sales operations in 17 countries, we employ more than 200 commercial sales personnel worldwide. And we serve additional international markets through relationships with valued distributors. In all, our technologies are currently approved for use in more than 30 countries, and we continue to pursue regulatory approvals in more regions.

Glaukos is excited to announce that we have acquired Avedro, Inc.!